Cytovale, a San Francisco–based diagnostics company focused on early sepsis detection, was in the spotlight this week as it advanced both its IntelliSep clinical evidence and its go‑to‑market strategy. The company is positioning its FDA‑cleared, rapid host‑response test as a core decision‑support tool for emergency departments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
New multicenter outcomes data from the Franciscan Missionaries of Our Lady Health system showed IntelliSep use in more than 34,000 ED patients was associated with a roughly 19% relative reduction in sepsis mortality and a 30% cut in blood culture utilization. The results also pointed to more patients being safely discharged without an increase in revisit rates, suggesting operational as well as clinical benefits.
A peer‑reviewed JACEP Open study using 100 real patient cases found that adding IntelliSep results to standard data changed or reinforced ED physicians’ decisions in 86% of 1,040 evaluations. The test improved diagnostic accuracy and boosted physician confidence by 19%, supporting Cytovale’s pitch that its eight‑minute assay can standardize and accelerate sepsis risk assessment.
Cytovale also created its first chief marketing officer role, appointing MedTech veteran Eric Khairy to lead global marketing and scale IntelliSep’s adoption. Khairy previously helped drive Inari Medical’s revenue from $6 million to $600 million and supported its path from startup to a $1 billion IPO and eventual $4.9 billion acquisition.
The company increased industry visibility by promoting IntelliSep at Becker’s Healthcare 16th Annual Meeting, where it is targeting C‑suite, quality, and clinical leaders with a message around sepsis performance, resource stewardship, and financial outcomes. Concurrently, Cytovale amplified media coverage from InvestigateTV that highlights sepsis diagnostic challenges and underscores unmet needs in ED risk stratification.
LinkedIn communications tied IntelliSep’s role to broader public health themes during National Public Health Week, emphasizing early infection risk assessment and ED decision‑making as levers for system‑level impact. Overall, the week underscored Cytovale’s push to pair growing clinical and real‑world evidence with expanded commercial infrastructure, aiming to strengthen hospital adoption and long‑term positioning in sepsis diagnostics.